<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953195</url>
  </required_header>
  <id_info>
    <org_study_id>2021-309</org_study_id>
    <nct_id>NCT04953195</nct_id>
  </id_info>
  <brief_title>Thyroid Replacement Therapy in Patients With Subclinical Hypothyroidism</brief_title>
  <official_title>Effect of Thyroid Replacement Therapy on Thyroid Structure in Patients With Subclinical Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this experiment is to compared the changes of thyroid function, anti-thyroid&#xD;
      peroxidase antibody, anti-thyroglobulin antibody, thyroid magnetic resonance T1-mapping and&#xD;
      various metabolic indexes from baseline to the end of treatment (after the thyroid function&#xD;
      had been normal for more than three months)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with autoimmune thyroiditis with mild subclinical hypothyroidism, the study&#xD;
      period will include a screening period of not more than 30 days, and a 12-week treatment&#xD;
      period compared to baseline. At completion of treatment, Thyroid Stimulating Hormone(TSH),&#xD;
      free thyroxine (FT4)ï¼Œfree thyroxine (FT3) will be included. The changes of anti-thyroglobulin&#xD;
      antibody, anti-thyroglobulin antibody, T1-mapping and metabolic indexes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thyroid Stimulating Hormone changes</measure>
    <time_frame>Thyroid Stimulating Hormone Changes from baseline and 12 weeks during follow-up</time_frame>
    <description>Thyroid Stimulating Hormone Changes from baseline and 12 weeks during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>free thyroxine changes</measure>
    <time_frame>free thyroxine changes from baseline and 12 weeks during follow-up</time_frame>
    <description>free thyroxine changes from baseline and 12 weeks during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1-mapping values of Thyroid MRI</measure>
    <time_frame>T1-mapping values of Thyroid MRI Changes from baseline and 12 weeks during follow-up</time_frame>
    <description>T1-mapping values of Thyroid MRI Changes from baseline and 12 weeks during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free triiodothyronine changes</measure>
    <time_frame>Free triiodothyronine changes Changes from baseline and 12 weeks during follow-up</time_frame>
    <description>Free triiodothyronine changes Changes from baseline and 12 weeks during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-thyroid peroxidase antibody changes</measure>
    <time_frame>anti-thyroid peroxidase antibody changes from baseline and 12 weeks during follow-up</time_frame>
    <description>anti-thyroid peroxidase antibody changes from baseline and 12 weeks during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-thyroglobulin antibody changes</measure>
    <time_frame>anti-thyroglobulin antibody changes from baseline and 12 weeks during follow-up</time_frame>
    <description>anti-thyroglobulin antibody changes from baseline and 12 weeks during follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Subclinical Hypothyroidisms</condition>
  <arm_group>
    <arm_group_label>levothyroxine sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levothyroxine sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Sodium Tablets</intervention_name>
    <description>Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,</description>
    <arm_group_label>levothyroxine sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women between the ages of 18 and 75;&#xD;
&#xD;
          -  Diagnostic criteria for mild subclinical hypothyroidism :TSH&gt;10mIU/L, thyroxine and&#xD;
             free thyroxine levels were normal&#xD;
&#xD;
          -  Positive thyroglobulin antibody and/or Thyroperoxidase antibody&#xD;
&#xD;
          -  No previous use of drugs affecting thyroid function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The contraindications indicated in the Chinese instructions of the drug&#xD;
&#xD;
          -  Liver function impairment&#xD;
&#xD;
          -  Renal function impairment&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Mental disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao-Yang Hospital, Capital Medical University, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Liu, MD</last_name>
    <phone>861085231710</phone>
    <email>liujia0116@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaomeng Sun, MD</last_name>
    <phone>861085231711</phone>
    <email>beijingxiaosun2010@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia liu, MD</last_name>
      <phone>861085231710</phone>
      <email>liujia0116@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Guang Wang</investigator_full_name>
    <investigator_title>Director of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

